In fact, a recent review [18] confirmed the milder disease course of acute infection in children, and it also analyzed several different therapeutic options addressed in current literature (including antivirals, immunomodulation, aerosol, probiotics, lactoferrin, antibiotics and vaccines) without finding enough strong evidence to derive conclusions about the efficacy of these options on reducing both short- and long-term consequences of COVID-19 in children. This evidence concerns the gene LTF and COVID-19.